Targeted radiotherapy with radiolabeled somatostatin analogs

Nicolas, Guillaume and Giovacchini, Giampiero and Müller-Brand, Jan and Forrer, Flavio. (2011) Targeted radiotherapy with radiolabeled somatostatin analogs. Endocrinology and metabolism clinics of North America, Vol. 40, H. 1 , S. 187-204, ix-x.

Full text not available from this repository.

Official URL: http://edoc.unibas.ch/dok/A6007524

Downloads: Statistics Overview


Targeted radiopeptide therapy with (90)Yttrium- or (177)Lutetium-labeled somatostatin analogs has been proven to improve significantly quality of life and survival in patients suffering from metastatic or unresectable neuroendocrine tumors (NETs). Roughly 25% of patients achieve partial remission; progression-free survival is estimated to be 30 to 40 months. A wide range of protocols using different somatostatin analogs, isotopes, injected activity per cycle of administration, and number of cycles are reported. More patient-based therapy protocols are under development, taking into consideration the complexity of NET cell biology, dosimetric issues, and the availability of different radiolabeled analogs. This article reviews the effectiveness and safety of the different protocols and discusses several clinical algorithms used in an attempt to optimize targeted radiopeptide therapy.
Faculties and Departments:03 Faculty of Medicine > Bereich Querschnittsfächer (Klinik) > Radiologie USB > Nuklearmedizin (Wild)
03 Faculty of Medicine > Departement Klinische Forschung > Bereich Querschnittsfächer (Klinik) > Radiologie USB > Nuklearmedizin (Wild)
UniBasel Contributors:Forrer, Flavio
Item Type:Article, refereed
Article Subtype:Further Journal Contribution
Publisher:W. B. Saunders
Note:Publication type according to Uni Basel Research Database: Journal item
Last Modified:25 Oct 2013 08:32
Deposited On:25 Oct 2013 08:32

Repository Staff Only: item control page